Schäbitz WR, Köhrmann M, Schellinger PD, Minnerup J, Fisher M. Embolic stroke of undetermined source: gateway to a new stroke entity? Am J Med. 2020;133(7):795–801.

Article  Google Scholar 

Saver JL. Cryptogenic stroke. N Engl J Med. 2016;375(11): e26.

Article  Google Scholar 

Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13(4):429–38.

Article  Google Scholar 

Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke of undetermined source: a systematic review and clinical update. Stroke. 2017;48(4):867–72.

Article  Google Scholar 

Dussault C, Toeg H, Nathan M, Wang ZJ, Roux JF, Secemsky E. Electrocardiographic monitoring for detecting atrial fibrillation after ischemic stroke or transient ischemic attack: systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2015;8(2):263–9.

Article  Google Scholar 

Ziegler PD, Rogers JD, Ferreira SW, Nichols AJ, Richards M, Koehler JL, et al. Long-term detection of atrial fibrillation with insertable cardiac monitors in a real-world cryptogenic stroke population. Int J Cardiol. 2017;1(244):175–9.

Article  Google Scholar 

Komatsu T, Iguchi Y, Arai A, Sakuta K, Sakai K, Terasawa Y, et al. Large but nonstenotic carotid artery plaque in patients with a history of embolic stroke of undetermined source. Stroke. 2018;49(12):3054–6.

Article  Google Scholar 

Zhang AJ, Dhruv P, Choi P, Bakker C, Koffel J, Anderson D, et al. A systematic literature review of patients with carotid web and acute ischemic stroke. Stroke. 2018;49(12):2872–6.

Article  Google Scholar 

Navi BB, Kasner SE, Elkind MSV, Cushman M, Bang OY, DeAngelis LM. Cancer and embolic stroke of undetermined source. Stroke. 2021;52(3):1121–30.

Article  Google Scholar 

Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378(23):2191–201.

Article  Google Scholar 

Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019;380(20):1906–17.

Article  Google Scholar 

• Ntaios G, Georgiopoulos G, Perlepe K, Sirimarco G, Strambo D, Eskandari A, et al. A tool to identify patients with embolic stroke of undetermined source at high recurrence risk. Neurol 2019;93(23):e2094–104. This study proposed a score to identify ESUS patients with low or high probability of new onset AF to help decide which patients would benefit from long term cardiac monitoring.

Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370(26):2467–77.

Article  Google Scholar 

Wachter R, Gröschel K, Gelbrich G, Hamann GF, Kermer P, Liman J, et al. Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AFRANDOMISED): an open-label randomised controlled trial. Lancet Neurol. 2017;16(4):282–90.

Article  Google Scholar 

Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370(26):2478–86.

Article  Google Scholar 

Arboix A, Alió J. Cardioembolic stroke: clinical features, specific cardiac disorders and prognosis. Curr Cardiol Rev. 2010;6(3):150–61.

Article  Google Scholar 

Ioannidis SG, Mitsias PD. Patent foramen ovale in cryptogenic ischemic stroke: direct cause, risk factor, or incidental finding? Front Neurol. 2020;11:567.

Article  Google Scholar 

• Kent DM, Saver JL, Kasner SE, Nelson J, Carroll JD, Chatellier G, et al. Heterogeneity of treatment effects in an analysis of pooled individual patient data from randomized trials of device closure of patent foramen ovale after stroke. JAMA. 2021;326(22):2277–86. This study reported heterogeneity of treatment effect of PFO closure on stroke recurrence based on PASCAL classification system. PFO closure was associated with a 90% relative risk reduction for patients in PASCAL probable category (high RoPE score and high risk PFO features.

• Messé SR, Gronseth GS, Kent DM, Kizer JR, Homma S, Rosterman L, et al. Practice advisory update summary: patent foramen ovale and secondary stroke prevention: report of the Guideline Subcommittee of the American Academy of Neurology. Neurol. 2020;94(20):876–85. This is the latest guideline issued by AAN regarding PFO closure.

• Ospel JM, Singh N, Marko M, Almekhlafi M, Dowlatshahi D, Puig J, et al. Prevalence of ipsilateral nonstenotic carotid plaques on computed tomography angiography in embolic stroke of undetermined source. Stroke. 2020;51(6):1743–9. Highlights the emerging causes of ESUS.

• Kamtchum-Tatuene J, Wilman A, Saqqur M, Shuaib A, Jickling GC. Carotid plaque with high-risk features in embolic stroke of undetermined source: systematic review and meta-analysis. Stroke. 2020;51(1):311–4. Highlights the emerging causes of ESUS.

• Labeyrie MA, Serrano F, Civelli V, Jourdaine C, Reiner P, Saint-Maurice JP, et al. Carotid artery webs in embolic stroke of undetermined source with large intracranial vessel occlusion. Int J Stroke. 2021;16(4):392–5. Highlights the emerging causes of ESUS.

Bang OY, Chung JW, Lee MJ, Seo WK, Kim GM, Ahn MJ, et al. Cancer-related stroke: an emerging subtype of ischemic stroke with unique pathomechanisms. J Stroke. 2020;22(1):1–10.

Article  Google Scholar 

• Salehi Omran S, Hartman A, Zakai NA, Navi BB. Thrombophilia testing after ischemic stroke. Stroke. 2021;52(5):1874–84. https://www.ahajournals.org/doi/10.1161/STROKEAHA.120.032360. Highlights the inherited and acquired causes of thrombophilia and utility of work up in stroke patients.

Kijima Y, Gevorgyan R, McWilliams JP, Miller N, Noureddin N, Tobis JM. Usefulness of transcranial Doppler for detecting pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia. Am J Cardiol. 2016;117(7):1180–4.

Article  Google Scholar 

• Ischemic stroke and pulmonary arteriovenous malformations: a review. Neurol. 2022. https://doi.org/10.1212/WNL.0000000000200275. Highlights the emerging causes of ESUS.

The role of transcranial Doppler monitoring in patients with multi‐territory acute embolic strokes: a review - Kargiotis - 2019 - Journal of Neuroimaging - Wiley Online Library [Internet]. [cited 7 Jun 2022]. Available from: https://onlinelibrary.wiley.com/doi/10.1111/jon.12602

Ono H, Inoue T, Iijima A, Tanishima T, Tamura A, Saito I. Recurrent embolic stroke caused by large cavernous carotid aneurysm: stroke recurrence prevention with high-flow bypass followed by proximal occlusion. Asian J Neurosurg. 2018;13(3):901–5.

Article  Google Scholar 

Fuentes B, Gutiérrez-Zúñiga R, Díez-Tejedor E. It’s time to say goodbye to the ESUS construct. Front Neurol [Internet]. 2020;11 [cited 10 May 2022]. Available from: https://www.frontiersin.org/article/10.3389/fneur.2020.00653

Diener HC, Easton JD, Granger CB, Cronin L, Duffy C, Cotton D, et al. Design of randomized, double-blind, evaluation in secondary stroke prevention comparing the efficacy and safety of the oral thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with embolic stroke of undetermined source (RE-SPECT ESUS). Int J Stroke Off J Int Stroke Soc. 2015;10(8):1309–12.

Geisler T, Poli S, Meisner C, Schreieck J, Zuern CS, Nägele T, et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design. Int J Stroke Off J Int Stroke Soc. 2017;12(9):985–90.

Article  Google Scholar 

• Poli S. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS). In Lyon France; 2022. The most recent trial that compared widely used DOAC Eliquis to Aspirin for ESUS.

Kamel H, Longstreth WT, Tirschwell DL, Kronmal RA, Broderick JP, Palesch YY, et al. The atrial cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke randomized trial: rationale and methods. Int J Stroke Off J Int Stroke Soc. 2019;14(2):207–14.

Article  Google Scholar 

Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–236.

Article  Google Scholar 

Grotta JC. Antiplatelet therapy after ischemic stroke or TIA. N Engl J Med. 2018;379(3):291–2.

Article  Google Scholar 

Sposato LA, Cipriano LE, Saposnik G, Ruíz Vargas E, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 2015;14(4):377–87.

Article  Google Scholar 

Albers GW, Bernstein R, Brachmann J, Camm AJ, Fromm P, Goto S, et al. Reexamination of the embolic stroke of undetermined source concept. Stroke. 2021;52(8):2715–22.

Article  Google Scholar 

Fonseca AC, Alves P, Inácio N, Marto JP, Viana-Baptista M, Pinho-E-Melo T, et al. Patients with undetermined stroke have increased atrial fibrosis: a cardiac magnetic resonance imaging study. Stroke. 2018;49(3):734–7.

Article  Google Scholar 

Jordan K, Yaghi S, Poppas A, Chang AD, Mac Grory B, Cutting S, et al. Left atrial volume index is associated with cardioembolic stroke and atrial fibrillation detection after embolic stroke of undetermined source. Stroke. 2019;50(8):1997–2001.

Article  Google Scholar